Top

Published in:

Open Access 01-12-2021 | Metastasis | Research

Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Authors: Yuanji Xu, Zijie Wu, Wangzhong Ye, Youping Xiao, Wei Zheng, Qinyan Chen, Penggang Bai, Zhizhong Lin, Chuanben Chen

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

To explore the combined predictive value of serum uric acid (SUA) and tumor response to induction chemotherapy (IC) in locally advanced nasopharyngeal carcinoma (LANPC) patients receiving IC followed by concurrent chemoradiation therapy (CCRT).

Methods

A total of 341 LANPC patients treated with IC + CCRT were enrolled in this retrospective study. Overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) were compared by the Kaplan-Meier analysis and the log-rank test, and multivariable survival analysis was carried out to investigate the independent prognostic factors.

Results

Univariate analysis showed that a low SUA level and unsatisfactory tumor response to two cycles of IC both were negative predictors for OS, PFS, and DMFS in patients with LANPC. multivariable analysis demonstrated that the SUA level after two cycles of IC was an independent prognostic factor for OS (P = 0.012) but of borderline significance for PFS and DMFS (P = 0.055 and P = 0.067, respectively). Furthermore, tumor response to IC was of independent significance for predicting OS, PFS, and DMFS, respectively. Finally, LANPC patients with satisfactory tumor response and a high SUA level after two cycles of IC had a better OS, PFS, and DMFS than those with unsatisfactory tumor response and a low SUA level.

Conclusion

The SUA level and the tumor response to two cycles of IC had predictive value for LANPC patients treated with IC plus CCRT. However, more aggressive therapeutic strategies are recommended for those with a low SUA level and unsatisfactory tumor response to two cycles of IC.

Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–24. https://doi.org/10.1016/S0140-6736(15)00055-0.CrossRefPubMed

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Cancer Netw. 2018;16(5):479–90. https://doi.org/10.6004/jnccn.2018.0026.CrossRef

Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20. https://doi.org/10.1016/S1470-2045(16)30410-7.CrossRefPubMed

Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and Cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–35. https://doi.org/10.1056/NEJMoa1905287.CrossRefPubMed

Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. https://doi.org/10.1016/S0140-6736(19)30956-0.CrossRefPubMed

Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35(5):498–505. https://doi.org/10.1200/JCO.2016.67.4119.CrossRefPubMed

Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, et al. The prognostic value of plasma Epstein-Barr viral DNA and tumor response to Neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–9. https://doi.org/10.1016/j.ijrobp.2015.08.003.CrossRefPubMed

Peng H, Chen L, Zhang Y, Li WF, Mao YP, Liu X, et al. The tumour response to induction chemotherapy has prognostic value for long-term survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma. Sci Rep. 2016;6(1):24835. https://doi.org/10.1038/srep24835.CrossRefPubMedPubMedCentral

Xu C, Yang SP, Zhang Y, Tang LL, Zhou GQ, Liu X, et al. Neutropenia during the first cycle of induction chemotherapy is prognostic for poor survival in Locoregionally advanced nasopharyngeal carcinoma: a real-world study in an endemic area. Cancer Res Treat. 2018;50(3):777–90. https://doi.org/10.4143/crt.2017.255.CrossRefPubMed

10.

Huang CL, Sun ZQ, Guo R, Liu X, Mao YP, Peng H, et al. Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in Locoregionally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2019;104(2):355–61. https://doi.org/10.1016/j.ijrobp.2019.01.007.CrossRefPubMed

11.

Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1(1):16. https://doi.org/10.1186/2001-1326-1-16.CrossRefPubMedPubMedCentral

12.

Crohns M, Saarelainen S, Kankaanranta H, Moilanen E, Alho H, Kellokumpu-Lehtinen P. Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy. Free Radic Res. 2009;43(7):646–57. https://doi.org/10.1080/10715760902942824.CrossRefPubMedPubMedCentral

13.

Haen SP, Eyb V, Mirza N, Naumann A, Peter A, Löffler MW, et al. Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies. J Cancer Res Clin Oncol. 2017;143(5):759–71. https://doi.org/10.1007/s00432-017-2348-z.CrossRefPubMed

14.

Lin H, Lin HX, Ge N, Wang HZ, Sun R, Hu WH. Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. Radiat Oncol. 2013;8(1):121. https://doi.org/10.1186/1748-717X-8-121.CrossRefPubMedPubMedCentral

15.

Du XJ, Chen L, Li WF, Tang LL, Mao YP, Guo R, et al. Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma. Head Neck. 2017;39(3):492–7. https://doi.org/10.1002/hed.24631.CrossRefPubMed

16.

Amin MB. American joint committee on Cancer cancer staging manual. 8th ed. New York: Springer; 2016.

17.

Lin S, Pan J, Han L, Guo Q, Hu C, Zong J, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol. 2014;110(3):385–9. https://doi.org/10.1016/j.radonc.2014.01.011.CrossRefPubMed

18.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

19.

Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858–62. https://doi.org/10.1073/pnas.78.11.6858.CrossRefPubMedPubMedCentral

20.

Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143(3):355–66. https://doi.org/10.1016/j.cell.2010.09.043.CrossRefPubMedPubMedCentral

21.

Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, et al. Major histocompatibility complex class I related chain a/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer. 2011;11(1):194. https://doi.org/10.1186/1471-2407-11-194.CrossRefPubMedPubMedCentral

22.

Vigano L, Darwish SS, Rimassa L, Cimino M, Carnaghi C, Donadon M, et al. Progression of colorectal liver metastases from the end of chemotherapy to resection: a new contraindication to surgery? Ann Surg Oncol. 2018;25(6):1676–85. https://doi.org/10.1245/s10434-018-6387-8.CrossRefPubMed

23.

Li S, Wang Q, Mei J, Wang J, Zhong X, Ling Y, et al. Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 cases. J Cancer. 2019;10(20):5007–14. https://doi.org/10.7150/jca.35355.CrossRefPubMedPubMedCentral

24.

Shiraishi T, Sasaki T, Ikeda K, Tsukada Y, Nishizawa Y, Ito M. Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer. BMC Cancer. 2019;19(1):1222. https://doi.org/10.1186/s12885-019-6424-4.CrossRefPubMedPubMedCentral

25.

Nougaret S, Rouanet P, Molinari N, Pierredon MA, Bibeau F, Azria D, et al. MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy. Radiology. 2012;263(2):409–18. https://doi.org/10.1148/radiol.12111263.CrossRefPubMed

26.

Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2012;23(5):1287–92. https://doi.org/10.1093/annonc/mdr401.CrossRefPubMed

27.

Farrell PJ. Epstein-Barr virus and Cancer. Annu Rev Pathol. 2019;14(1):29–53. https://doi.org/10.1146/annurev-pathmechdis-012418-013023.CrossRefPubMed

28.

Li J, Chen QY, He J, Li ZL, Tang XF, Chen SP, et al. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 2015;4(2):e976507. https://doi.org/10.4161/23723556.2014.976507.CrossRefPubMedPubMedCentral

29.

Ni W, Qi W, Xu F, Cao W, Xu C, Chen J, et al. Prognostic value of nasopharynx tumour volume in local-regional advanced nasopharyngeal carcinoma. Ann Transl Med. 2020;8(5):223. https://doi.org/10.21037/atm.2020.01.03.CrossRefPubMedPubMedCentral

30.

Chen BB, Lu SY, Peng H, Sun FF, Zhu J, Wang J, et al. Comparison of long-term outcomes and Sequelae between children and adult nasopharyngeal carcinoma treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2020;106(4):848–56. https://doi.org/10.1016/j.ijrobp.2019.11.035.CrossRefPubMed

Title: Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma
Authors: Yuanji Xu
Zijie Wu
Wangzhong Ye
Youping Xiao
Wei Zheng
Qinyan Chen
Penggang Bai
Zhizhong Lin
Chuanben Chen
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08285-7

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and postoperative recurrence

TINCR inhibits the proliferation and invasion of laryngeal squamous cell carcinoma by regulating miR-210/BTG2

Association of advanced age and cancer history with autoimmune disease in melanoma patients: a cross-sectional study

Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells

nPTD classification: an updated classification of gastric cancer location for function preserving gastrectomy based on physiological lymphatic flow